AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 11.49 |
Market Cap | 1.43B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.95 |
PE Ratio (ttm) | -30 |
Forward PE | n/a |
Analyst | Buy |
Ask | 36.61 |
Volume | 301,729 |
Avg. Volume (20D) | 269,993 |
Open | 30.20 |
Previous Close | 30.03 |
Day's Range | 28.50 - 30.24 |
52-Week Range | 27.69 - 76.98 |
Beta | undefined |
About IMCR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (N...
Analyst Forecast
According to 12 analyst ratings, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is $66.5, which is an increase of 133.33% from the latest price.